Evidence map›Paper›PMID 30932357›Full record

ArticleBiotechnology progress2019

Development of a novel, high-throughput screening tool for efficient perfusion-based cell culture process development.

Thomas M Gagliardi, Rahul Chelikani, Yang Yang, Gioia Tuozzolo, Hang Yuan

Abstract read
In one paragraph

Article in Biotechnology progress, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Thomas M GagliardiUpstream Development, Bioprocess Development, Shire, Lexington, Massachusetts.ORCID 0000-0001-6118-7954
Rahul ChelikaniUpstream Development, Bioprocess Development, Shire, Lexington, Massachusetts.
Yang YangUpstream Development, Bioprocess Development, Shire, Lexington, Massachusetts.
Gioia TuozzoloUpstream Development, Bioprocess Development, Shire, Lexington, Massachusetts.
Hang YuanUpstream Development, Bioprocess Development, Shire, Lexington, Massachusetts.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Perfusion technology has been successfully used for the commercial production of biotherapeutics, in particular unstable recombinant proteins, for more than a decade. However, there has been a general lack of high-throughput cell culture tools specifically for perfusion-based cell culture processes. Here, we have developed a high-throughput cell retention operation for use with the ambr® 15 bioreactor system. Experiments were run in both 24 and 48 reactor configurations for comparing perfusion mimic models, media development, and clone screening. Employing offline centrifugation for cell retention and a variable volume model developed with MATLAB computational software, the established screening model has demonstrated cell culture performance, productivity, and product quality were comparable to bench scale bioreactors. The automated, single use, high-throughput perfusion mimic is a powerful tool that enables us to have rapid and efficient process development of perfusion-based cell culture processes.

Indexed as

Batch Cell Culture TechniquesHigh-Throughput Screening AssaysAnimalsBioreactorsCells, CulturedCHO CellsCricetinaeCricetuluscell culturehigh throughputperfusionprocess development

Identifiers

PMID30932357
PMCPMC7079109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.